15 February 2011
New research has hinted at the potentially beneficial effects of drinking red wine when undergoing chemotherapy treatment.
According to a study conducted at the Lerner Research Institute in Cleveland, US, reservatol - a compound commonly found in red wines - can actually suppress chemotherapy resistance in breast cancer cells.
The researchers looked at the impact resveratrol had on the efficacy of rapamycin - a relatively new chemotherapy for cancer treatment.
They found in previous clinical trials that breast cancer cells quickly develop resistance to the drug, but claim resveratrol appears to mitigate the development of drug resistance.
Writing in research journal Cancer Letters, Professor Charis Eng, chair of the Genomic Medicine Institute of Cleveland Clinic's Lerner Research Institute, said: "If these observations hold true in the clinic setting, then enjoying a glass of red wine or eating a bowl of boiled peanuts - which has a higher resveratrol content than red wine - before rapamycin treatment for cancer might be a prudent approach."
In 2008, Cancer Research UK warned against the overblown remarks in the media that red wine can actually prevent breast cancer - suggesting that the research had been misrepresented.
Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy is © Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated.
1 Eng, Charis. "Red wine compound increases anti-tumor effect of rapamycin". Cancer Letters. Monday, February 14th 2011.
2 "No, red wine doesn’t prevent breast cancer". Cancer Research UK. Tuesday, July 8th 2008.
Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.